Nanomaterials comprising carbonates

A compound of Formula I′:

• or its N-oxide, or a pharmaceutically acceptable salt thereof, wherein
• L1 is absent, C1-6 alkylenyl, or C2-6 heteroalkylenyl;
• each L2 is independently optionally substituted C2-15 alkylenyl, or optionally substituted C3-15 heteroalkylenyl;
• L is absent, optionally substituted C1-10 alkylenyl, or optionally substituted C2-10 heteroalkylenyl;
• L3 is absent, optionally substituted C1-10 alkylenyl, or optionally substituted C2-10 heteroalkylenyl;
• X is absent, —OC(O)—, —C(O)O—, or —OC(O)O—;
• each R is independently hydrogen,
• or an optionally substituted group selected from C
• 6-20 aliphatic, 3- to 12-membered cycloaliphatic, 7- to 12-membered bridged bicyclic comprising 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl;
• R1 is hydrogen, optionally substituted phenyl, optionally substituted 3- to 7-membered cycloaliphatic, optionally substituted 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 5- to 6-membered monocyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, —OR2, —C(O)OR2, —C(O)SR2, —OC(O)R2, —OC(O)OR2, —CN, —N(R2)2, —C(O)N(R2)2, —S(O)2N(R2)2, —NR2C(O)R2, —OC(O)N(R2)2, —N(R2)C(O)OR2, —NR2S(O)2R2, —NR2C(O)N(R2)2, —NR2C(S)N(R2)2, —NR2C(NR2)N(R2)2, —NR2C(CHR2)N(R2)2, —N(OR2)C(O)R2, —N(OR2)S(O)2R2, —N(OR2)C(O)OR2, —N(OR2)C(O)N(R2)2, —N(OR2)C(S)N(R2)2, —N(OR2)C(NR2)N(R2)2, —N(OR2)C(CHR2)N(R2)2, —C(NR2)N(R2)2, —C(NR2)R2, —C(O)N(R2)OR2, —C(R2)N(R2)2C(O)OR2, —CR2(R3)2, —OP(O)(OR2)2, or —P(O)(OR2)2;
• or
• R1 is
• or a ring selected from 3- to 7-membered cycloaliphatic and 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloaliphatic or heterocyclyl ring is optionally substituted with 1-4 R
• 2 or R3 groups;
• each R2 is independently hydrogen, oxo, —CN, —NO2, —OR4, —S(O)2R4, —S(O)2N(R4)2, —(CH2)n—R4, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 3- to 7-membered cycloaliphatic, 5- to 6-membered monocyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• or
• two occurrences of R2, taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
• each R3 is independently —(CH2)n—R4;
• or
• two occurrences of R3, taken together with the atom(s) to which they are attached, form optionally substituted 5- to 6-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
• each R4 is independently hydrogen, —OR5, —N(R5)2, —OC(O)R5, —OC(O)OR5, —CN, —C(O)N(R5)2, —NR5C(O)R5, —OC(O)N(R5)2, —N(R5)C(O)OR5, —NR5S(O)2R5, —NR5C(O)N(R5)2, —NR5C(S)N(R5)2, —NR5C(NR5)N(R5)2, or
• each R5 is independently hydrogen or optionally substituted C1-6 aliphatic;
• or
• two occurrences of R5, taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
• each R6 is independently C4-12 aliphatic;
• and
• each n is independently 0 to 4.